Janux Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Financial amounts below are in U.S. dollars; statements present amounts in thousands unless noted.
Business context
Janux is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its TRACTr and TRACIr platforms. It has no product sales; reported revenue is from its Merck collaboration. JANX007 and JANX008 were in Phase 1 trials, while most other programs remained preclinical or in discovery.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Collaboration revenue | $2.048 million | $1.589 million | +$0.459 million |
| Research and development expense | $15.865 million | $10.184 million | +$5.681 million |
| General and administrative expense | $6.464 million | $4.947 million | +$1.517 million |
| Operating loss | $20.281 million | $13.542 million | Loss increased $6.739 million |
| Interest income | $2.822 million | $0.132 million | +$2.690 million |
| Net loss | $17.459 million | $13.410 million | Loss increased $4.049 million |
| Basic and diluted loss per share | $0.42 | $0.32 | Loss per share increased |
| Net cash used in operating activities | $13.911 million | $11.522 million | Use increased $2.389 million |
Revenue increased 29% year over year, reflecting more research-service hours under the Merck agreement. R&D expense rose 56%, driven by higher indirect costs, preclinical and unallocated program costs, and JANX007 spending; JANX008 direct costs declined. G&A expense increased 31%. Higher interest income partly offset increased operating losses. Collaboration revenue came from one customer, Merck; there is no product revenue, so product gross margins are not applicable.
At March 31, 2023, cash and cash equivalents were $30.355 million, short-term investments were $286.520 million, and restricted cash was $0.816 million. Management reported $317.7 million in cash, cash equivalents, restricted cash, and short-term investments; $0.8 million was restricted. Total assets were $352.956 million, current liabilities were $16.114 million, and stockholders’ equity was $311.264 million. The filing reports no borrowings; operating lease liabilities totaled $25.540 million, including $1.356 million current. Minimum future lease payments were $37.429 million.
Cash, cash equivalents, and restricted cash declined $21.071 million during the quarter. Investing cash use was $8.740 million, including net purchases of short-term investments and property and equipment; financing cash inflow was $1.580 million, mainly from option exercises. The accumulated deficit was $127.929 million. Stock-based compensation was $5.473 million.
Outlook, developments, and risks
- Management expects substantial operating losses and increased expenses for the foreseeable future. It believes existing cash, cash equivalents, and short-term investments will fund anticipated requirements for at least 12 months following the filing date, but says estimates depend on assumptions and additional capital will be needed to advance candidates through approval and commercialization.
- Janux anticipated an interim JANX007 clinical update in the second half of 2023. The first patient in the JANX008 Phase 1 trial was dosed in April 2023. The company expected to select a TROP2-TRACTr development candidate and submit an IND for JANX009 in 2023.
- The Merck agreement covers two selected targets. Janux recognized $2.0 million of collaboration revenue in Q1 and had $6.3 million of related deferred revenue at March 31, of which $4.9 million was current. Remaining research-service obligations for the second target were estimated to extend 1.4 years. Merck may terminate the agreement; milestone and royalty receipts depend on development and commercial success.
- A shelf registration permits offerings of up to $400 million. The $100 million ATM program had no shares sold before Janux terminated the Sale Agreement effective May 5, 2023; no termination penalty applied.
- Key risks include clinical failure or delay, patient enrollment, adverse events including cytokine release syndrome and healthy-tissue toxicity, dependence on third-party research and manufacturing, need for additional financing and possible dilution, and macroeconomic or banking-market disruption. The company reported no material legal proceedings and no material operating disruption from cited macroeconomic risks to date.
Important facts for investors to verify
- Progress, safety, enrollment, and timing of JANX007 and JANX008 trials, including the anticipated JANX007 update.
- Cash burn and the assumptions supporting management’s at-least-12-month runway estimate; timing and terms of any future financing.
- Merck research progress, recognition of deferred revenue, and the conditions for milestone and royalty payments.
- Delivery of the stated 2023 TROP2 candidate-selection and JANX009 IND milestones.
- Potential dilution from equity compensation or future offerings; the ATM program was terminated with no prior sales.